FibroBiologics Inc. (NASDAQ:FBLG – Get Free Report) has been given a consensus rating of “Reduce” by the five analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $74.00.
FBLG has been the topic of a number of recent research reports. Maxim Group cut FibroBiologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft downgraded shares of FibroBiologics to an “underperform” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a research note on Tuesday. Wall Street Zen upgraded shares of FibroBiologics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings upgraded shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, July 24th.
Check Out Our Latest Research Report on FibroBiologics
FibroBiologics Stock Performance
FibroBiologics (NASDAQ:FBLG – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.27. Equities research analysts predict that FibroBiologics will post -4.01 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of FBLG. AQR Capital Management LLC purchased a new stake in shares of FibroBiologics during the first quarter valued at $29,000. XTX Topco Ltd boosted its holdings in shares of FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of FibroBiologics in the second quarter worth approximately $49,000. Jane Street Group LLC purchased a new position in shares of FibroBiologics during the second quarter valued at approximately $60,000. Finally, Cerity Partners LLC lifted its position in FibroBiologics by 37.2% during the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares during the period.
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Featured Stories
- Five stocks we like better than FibroBiologics
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
